• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Osmotica Pharmaceutical Corp. - Product Pipeline Review - H2 2011 Product Image

Osmotica Pharmaceutical Corp. - Product Pipeline Review - H2 2011

  • ID: 1964541
  • November 2011
  • 26 pages
  • Global Markets Direct

Osmotica Pharmaceutical Corp. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Osmotica Pharmaceutical Corp. - Product Pipeline Review - H2 2011” provides data on the Osmotica Pharmaceutical Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Osmotica Pharmaceutical Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Osmotica Pharmaceutical Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Osmotica Pharmaceutical Corp. - Brief Osmotica Pharmaceutical Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Osmotica Pharmaceutical Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Osmotica Pharmaceutical Corp. Snapshot
Osmotica Pharmaceutical Corp. Overview
Key Information
Key Facts
Osmotica Pharmaceutical Corp. – Research and Development Overview
Key Therapeutic Areas
Osmotica Pharmaceutical Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Osmotica Pharmaceutical Corp. – Pipeline Products Glance
Osmotica Pharmaceutical Corp. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Osmotica Pharmaceutical Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Osmotica Pharmaceutical Corp. – Drug Profiles
Levodopa + Carbidopa
Product Description
Mechanism of Action
R&D Progress
OS-390
Product Description
Mechanism of Action
R&D Progress
OS-440
Product Description
Mechanism of Action
R&D Progress
OS–320
Product Description
Mechanism of Action
R&D Progress
Osmotica Pharmaceutical Corp. – Pipeline Analysis
Osmotica Pharmaceutical Corp. – Pipeline Products by Therapeutic Class
Osmotica Pharmaceutical Corp. - Pipeline Products By Target
Osmotica Pharmaceutical Corp. – Pipeline Products by Route of Administration
Osmotica Pharmaceutical Corp. – Pipeline Products by Molecule Type
Osmotica Pharmaceutical Corp. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 23, 2008: Osmotica Pharmaceutical Receives FDA Approval To Market Novel Forms Of Extended Release Venlafaxine HCl
Oct 09, 2008: Osmotica Pharmaceutical Corp And Upstate Pharma, LLC, A subsidiary Of UCB, Inc., Announce The Availability Of Venlafaxine Extended-Release Tablets
Financial Deals Landscape
Osmotica Pharmaceutical Corp., Deals Summary
Osmotica Pharmaceutical Corp., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Osmotica Pharmaceutical Enters Into Co-Marketing Agreement With Upstate Pharma
Osmotica Pharmaceutical Enters Into Co-Development Agreement With AAIPharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Osmotica Pharmaceutical Corp. – Pipeline by Therapy Area and Indication, H2 2011
Osmotica Pharmaceutical Corp. – Pipeline by Stage of Development, H2 2011
Osmotica Pharmaceutical Corp. – Monotherapy Products in Pipeline, H2 2011
Osmotica Pharmaceutical Corp. – Combination Treatment Modalities in Pipeline, H2 2011
Osmotica Pharmaceutical Corp. - Phase II, H2 2011
Osmotica Pharmaceutical Corp. - Pipeline By Therapeutic Class, H2 2011
Osmotica Pharmaceutical Corp. - Pipeline By Target, H2 2011
Osmotica Pharmaceutical Corp. – Pipeline By Route of Administration, H2 2011
Osmotica Pharmaceutical Corp. – Pipeline By Molecule Type, H2 2011
Osmotica Pharmaceutical Corp., Subsidiaries
Osmotica Pharmaceutical Corp., Deals Summary
Osmotica Pharmaceutical Enters Into Co-Marketing Agreement With Upstate Pharma
Osmotica Pharmaceutical Enters Into Co-Development Agreement With AAIPharma

List of Figures
Osmotica Pharmaceutical Corp. – Pipeline by Therapy Area and Indication, H2 2011
Osmotica Pharmaceutical Corp. – Pipeline by Stage of Development, H2 2011
Osmotica Pharmaceutical Corp. – Monotherapy Products in Pipeline, H2 2011
Osmotica Pharmaceutical Corp. – Combination Treatment Modalities in Pipeline, H2 2011
Osmotica Pharmaceutical Corp. – Pipeline By Therapeutic Class, H2 2011
Osmotica Pharmaceutical Corp. - Pipeline By Target, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos